Protocol Ledger

Therapeutic Cohort CVM · ClinicalTrials.gov API v2

Cardiovascular and Thrombosis: Phase II & III Clinical Trial Benchmarks

Protocol Ledger tracks 2,184 interventional Phase II and Phase III Cardiovascular and Thrombosis protocols registered from 2018 through 2026, including 831 active studies, 799 completed studies, and 245 early-stopped studies (11.22% overall; 23.47% of closed trials).

Median Enrollment: 102.5 participants Median Completed Span: 695 days California Share: 403 studies (18.5%)

1. Reconciled Cardiovascular and Thrombosis Execution & Stop-Cause Profile

Cardiovascular and Thrombosis Cohort Metrics (Publication 47c4426df7e9d67d5bfe)
Clinical Trial Metric Verified Value Operational Context
Total Phase II & III Protocols (2018 to 2026) 2,184 Deterministic primary MeSH and condition-keyword assignment
Active Concurrent Pipeline 831 Recruiting, enrolling by invitation, and active follow-up protocols
Completed vs Prematurely Stopped 799 / 245 23.47% closed-trial attrition ratio across 1,044 closed protocols
Slow Accrual vs Safety & Futility Stops 58 / 16 / 19 Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5)
Physical Hospital Site Disclosure Rate 75.2% Named hospital campus participations vs anonymized CRO site slots

2. Leading Consolidated Trial Sponsors Focused on Cardiovascular and Thrombosis

Consolidated Biopharma, Academic & Federal Sponsors (Cardiovascular and Thrombosis Primary Focus)
Sponsor Hub Sector Protocols Active Completed FDA NDA/BLA
EMS Biopharma Industry 47 13 8 0
University of Sao Paulo General Hospital Academic / Institutional Sponsor 34 6 6 0
Hanmi Pharmaceutical Company Limited Biopharma Industry 29 8 20 0
Arrowhead Pharmaceuticals Biopharma Industry 28 10 15 0
Chong Kun Dang Pharmaceutical Biopharma Industry 27 3 15 0
Population Health Research Institute Academic / Institutional Sponsor 23 10 11 0
Shenzhen Salubris Pharmaceuticals Co Biopharma Industry 23 9 13 0
University of Monastir Academic / Institutional Sponsor 21 7 10 0
Addpharma Biopharma Industry 16 4 11 0
Insmed Incorporated Biopharma Industry 16 5 9 0
Ottawa Heart Institute Research Academic / Institutional Sponsor 16 11 4 0
Beijing Suncadia Pharmaceuticals Co Biopharma Industry 15 7 8 0

3. Representative Multi-Center Phase II & III Cardiovascular and Thrombosis Studies

Indexed ClinicalTrials.gov v2 Study Dossiers in Cardiovascular and Thrombosis
NCT Study Protocol Brief Title Sponsor Phase Status
NCT07575672 Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure Second Affiliated Hospital, Zhejiang University, School of Medicine Phase III RECRUITING
NCT07303777 Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis Atom Therapeutics Co Phase II RECRUITING
NCT06475781 Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward) Foresee Pharmaceuticals Co Phase II RECRUITING
NCT07613294 A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk Eli Lilly and Company Phase III RECRUITING
NCT06736574 Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction Cytokinetics Phase III RECRUITING
NCT06772168 Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia CMG Pharmaceutical Co Phase III RECRUITING
NCT07687186 Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre Tasly Pharmaceutical Group Co Phase III RECRUITING
NCT06563895 Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant Eidos Therapeutics, a BridgeBio company Phase III RECRUITING
NCT07771465 A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy Kardigan Phase III RECRUITING
NCT07210723 A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy Kardigan Phase II/III RECRUITING
NCT07192952 A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction Bayer Phase III RECRUITING
NCT07188805 A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ve Bayer Phase III RECRUITING
NCT07448038 A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events Roche / Genentech Phase II RECRUITING
NCT07285655 A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD Liquidia Technologies Phase III RECRUITING
NCT05179876 A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option Johnson & Johnson / Janssen Phase III RECRUITING
NCT05836987 The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation Johns Hopkins University Phase III RECRUITING

Related Therapeutic Condition Hubs & Crosswalks

Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI